# ORATOR2 (NCT03210103)

> Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: HPV-associated oropharyngeal squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03210103
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Conditions: Oropharyngeal Cancer
- Interventions: Radiation; Transoral Surgery (TOS) + Neck Dissection
- Enrollment: 61
- Primary outcome: Overall Survival

## Some of the questions raised in the 38 most recent indexed sources

_Automated from the 38 newest of 48 indexed sources (Mar 2019 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- How surgeon credentialing and surgical outcomes in the transoral surgery arm compare with E3311 and MC1675
- Whether early closure leaves the trial too small and immature to compare oncologic outcomes between arms
- Whether the radiotherapy arm's event rate is consistent with real-world outcomes outside the trial
- Whether the trial should end routine transoral surgery as a de-escalation approach in HPV-positive disease

## Indexed commentary on ORATOR2 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 46 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=orator2-nct03210103

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03210103", "email": "<work email>"}; the inbox owner confirms by the emailed link.
